NCT04781088 2026-02-11Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerOhio State University Comprehensive Cancer CenterPhase 2 Active not recruiting38 enrolled